Table 2.

Summary of clinical trials regarding panitumumab

Protocol IDs	Title	Design	Status	Trial description
CTRU-PICCOLO-MO-05–7289	Phase III Randomized Study of Irinotecan Hydrochloride With Versus Without Panitumumab or Cyclosporine in Patients With Fluorouracil-Resistant Advanced or Metastatic Colorectal Cancer	Phase III, Randomized	Active	Arm I: Patients receive irinotecan on day 1. Arm II: Patients receive irinotecan on day 1 and oral cyclosporine three times a day on days 1–3. Arm III: Patients receive panitumumab followed by irinotecan on day 1. Single-agent panitumumab may be continued during breaks in chemotherapy treatment.
20080763	ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Subjects With KRAS Wild-Type Metastatic Colorectal Cancer	Phase III, Randomized	Active	The primary objective of this study is to compare the effect of panitumumab versus cetuximab on overall survival (OS) for chemorefractory metastatic colorectal cancer (mCRC) among subjects with wild-type Kirsten rat Sarcoma-2 virus (KRAS) tumors.
20060141	SPIRITT – Second-Line Panitumumab Irinotecan Treatment Trial	Phase II, Randomized	Active	Arm 1: FOLFIRI + Panitumumb Arm 2: FOLFIRI + Bevacizumab
NU-07I4	Phase II Randomized Study of Erlotinib Hydrochloride and Panitumumab With Versus Without Irinotecan Hydrochloride as Second-Line Therapy in Patients With Metastatic Colorectal Cancer	Phase II, Randomized	Active	Arm I: erlotinib once daily on days 1–14, panitumumab on day 1, and irinotecan. on day 1. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity. Arm II: erlotinib once daily on days 1–14 and panitumumab on day 1. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients receive irinotecan hydrochloride as in Arm I. Arm III: Patients receive erlotinib and panitumumab as in Arm II.
20070509	PEAK: A Phase 2 Study of Panitumumab Plus mFOLFOX6 vs Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer Subjects With Wild-Type KRAS Tumors	Phase II	Active	The primary objective of this study is to estimate the treatment effect on progression-free survival (PFS) of panitumumab relative to bevacizumab in combination with mFOLFOX6 chemotherapy as first-line therapy in subjects with tumors expressing wild-type KRAS, unresectable mCRC.
08–287	Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer	Phase II	Active	The purpose of this research study is to learn whether panitumumab helps treat colorectal cancer in participants who have not responded to treatment with cetuximab.
TTD-08-04	Safety and Efficacy Study of FOLFOX4+ Panitumumab vs FOLFIRI + Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases	Phase II	Active	The purpose of the study is to evaluate the efficacy and safety of the combination of Panitumumab with FOLFOX4 Chemotherapy or Panitumumab with FOLFIRI Chemotherapy in Subjects with Wild- Type KRAS Colorectal Cancer and liver-only Metastases.
BrUOG-CR-218	Panitumumab and Bevacizumab Maintenance After First-Line FOLFOX-Bevacizumab for Patients With Advanced Colorectal Cancer With Wild-Type Ras	Phase II	Active	Bevacizumab given at 7.5 mg/kg. every 3 weeks until disease progression. Panitumumab given at 9 mg/kg. every 3 weeks until disease progression. Primary Objective: To determine the safety of every 3 week panitumumab and bevacizumab as maintenance therapy for patients with metastatic colorectal cancer.